Esperion Shares Down 31.4% Wed.; Needham Issues Mid-Day Comments In Note, Says 'We Remain Confident in Efficacy and Safety Profile of Bempedoic Acid'; Maintains Strong Buy Rating, $94 Price Target
Paul Quintaro